Recent recognition of ULK1 as a target for ALS therapy has led to the development of new strategies that enable a systematic screening for phytochemicals with the potential to boost ULK1 activity in a manner that could translate into an essential therapeutic agent for ALS. This evidence concerns the gene ULK1 and amyotrophic lateral sclerosis.